H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $22 from $20 and keeps a Buy rating on the shares. The firm ...

UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the ridiculously cheap stocks to buy now. As of December 26, BioMarin ...

Cantor Fitzgerald analyst Li Watsek raised the firm’s price target on Ascendis Pharma (ASND) to $254 from $203 and keeps an Overweight rating on the shares. The firm updated its patient flow model for ...

Specialty drugs surpass pharma sales, reaching 52% of U.S. pharmaceutical sales in 2024, driven by immunology and oncology therapies.

Torrent also plans to raise Rs 1,500 crore via commercial paper to fund its acquisition of a controlling stake in JB ...

The average one-year price target for Athira Pharma (NasdaqCM:ATHA) has been revised to $4.08 / share. This is an increase of 700.00% from the prior estimate of $0.51 dated September 10, 2025. The ...

The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NasdaqGS:IPHA) has been revised to $6.89 / share. This is an increase of 12.56% from the prior estimate of $6.12 dated ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the 20 NYSE Stocks with the Lowest P/E Ratios. UBS maintained its Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on ...

Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated December 24, 2025.